新辅助化疗增加可切除非小细胞肺癌细胞毒性T细胞、组织驻留记忆T细胞及B细胞浸润
本研究比较511例接受新辅助化疗后手术(NCT)与直接手术(US)的可切除NSCLC患者的基因组、转录组及免疫图谱数据,发现NCT与细胞毒性CD8+ T细胞和CD20+ B细胞浸润增加相关,并增加CD8+CD103+及CD4+CD103+PD-1+TIM3-组织驻留记忆T细胞,但未影响T细胞受体克隆性、丰富度或肿瘤突变负荷,且NCT与血浆BDNF(TrkB)降低相关。
要点
- 新辅助化疗增加可切除NSCLC中细胞毒性CD8+ T细胞和CD20+ B细胞浸润。
- 新辅助化疗增加CD8+CD103+和CD4+CD103+PD-1+TIM3-组织驻留记忆T细胞。
- 新辅助化疗不影响T细胞受体克隆性、丰富度或肿瘤突变负荷。
核心结论
- 在可切除NSCLC中,新辅助化疗通过T细胞和B细胞募集以及向细胞毒性和记忆CD8+及CD4+记忆辅助T细胞的表型转变来促进抗肿瘤免疫。
研究设计与样本
- 比较511例接受新辅助化疗后手术(NCT)与直接手术(US)的可切除NSCLC患者的基因组、转录组和免疫图谱数据。
- 全外显子组测序:NCT=18,US=73;RNA微阵列:NCT=45,US=202;流式细胞术:NCT=17,US=39;多重免疫荧光:NCT=10,US=72;T细胞受体测序:NCT=16,US=63;循环细胞因子:NCT=18,US=73。
主要发现
- NCT与细胞毒性CD8+ T细胞和CD20+ B细胞浸润增加相关。
- NCT与CD8+CD103+和CD4+CD103+PD-1+TIM3-组织驻留记忆T细胞增加相关。
- 基因表达谱支持CD8+和CD4+ T细胞的记忆功能。
- NCT未影响T细胞受体克隆性、丰富度或肿瘤突变负荷。
- NCT与基线及术后第4周血浆BDNF(TrkB)降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The combination of programmed cell death protein-1 or programmed death-ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment of advanced NSCLC, but the mechanisms underlying this synergy remain incompletely understood. In this study, we explored the relationships between neoadjuvant chemotherapy and the immune microenvironment (IME) of resectable NSCLC to identify novel mechanisms by which chemotherapy may enhance the effect of immune checkpoint blockade. METHODS: Genomic, transcriptomic, and immune profiling data of 511 patients treated with neoadjuvant chemotherapy followed by surgery (NCT) versus upfront surgery (US) were compared with determined differential characteristics of the IMEs derived from whole-exome sequencing (NCT = 18; US = 73), RNA microarray (NCT = 45; US = 202), flow cytometry (NCT = 17; US = 39), multiplex immunofluorescence (NCT = 10; US = 72), T-cell receptor sequencing (NCT = 16 and US = 63), and circulating cytokines (NCT = 18; US = 73). RESULTS: NCT was associated with increased infiltration of cytotoxic CD8+ T cells and CD20+ B cells. Moreover, NCT was associated with increases in CD8+CD103+ and CD4+CD103+PD-1+TIM3- tissue resident memory T cells. Gene expression profiling supported memory function of CD8+ and CD4+ T cells. However, NCT did not affect T-cell receptor clonality, richness, or tumor mutational burden. Finally, NCT was associated with decreased plasma BDNF (TrkB) at baseline and week 4 after surgery. CONCLUSIONS: Our study supports that, in the context of resectable NSCLC, neoadjuvant chemotherapy promotes antitumor immunity through T and B cell recruitment in the IME and through a phenotypic change toward cytotoxic and memory CD8+ and CD4+ memory helper T cells.
引用
- Gaudreau PO, Negrao MV, Mitchell KG, et al. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2020. PMID: 33096269. doi:10.1016/j.jtho.2020.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。